Answers are grounded in this paper and cite their sources.
Shows that factor VIII replacement remains the standard of care in haemophilia A, highlighting limitations of non-replacement therapies in acute bleeding and surgery.
Prophylactic factor VIII (FVIII) has dramatically improved haemophilia A treatment, preventing joint bleeding and halting the deterioration of joint status. FVIII products with an extended plasma half-life further improve patients' quality of life and increase therapeutic adherence. New licensed classes of non-replacement products include prophylactic emicizumab, which is administered subcutaneously up to every 4 weeks. However, this drug is not suitable for acute bleeding episodes or management of major surgery, and long-term data on the impact of emicizumab on joint health, FVIII inhibitor development and thrombotic risk are awaited. Prophylaxis with FVIII replacement remains the standard of care in haemophilia A, with the aim of achieving a level of haemostasis control that allows patients to meet their lifestyle goals.
No takes yet. Share an insight, caveat, or question.
Aledort et al. (2019) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: